CJ 40010Alternative Names: CJ40010
Latest Information Update: 23 Dec 2015
At a glance
- Originator CJ HealthCare
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Enterovirus A infections
Most Recent Events
- 23 Dec 2015 Preclinical trials in Enterovirus A infections in South Korea (unspecified route) (CJ Heralthcare pipeline, December 2015)